Drive companies receive 25% preferential pricing against Sonrai’s standard commercial rates, a scoped Scientific Readiness and Evidence Strategy Assessment where required, and access to senior Sonrai scientists, with continuity of the same team where possible. Engagements are milestone-based, with clearly scoped deliverables and timelines, and are calibrated to each company’s stage, from seed through Series A and clinical stage. Founders can start with the scientific question that matters most today and scale the relationship as their program grows.